{"filings":[{"id":1719478,"accession_number":"0001867096-26-000055","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-07-17T20:20:39+00:00","items":["3.02","8.01"],"status":"ready","headline":"Xeris retires $33.5M of 2028 convertible notes via exchange and conversion","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged ~$23M principal of 8.00% Convertible Senior Notes due 2028 for ~5.0M shares and ~$23M cash.","Separately, a holder converted $10.5M principal into ~3.6M shares.","After transactions, no 2028 Notes remain outstanding; all cancelled.","Shares issued in exchange were unregistered, relying on Section 4(a)(2) exemption; conversion shares on Section 3(a)(9).","Company funded cash portion with liquidity on-hand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1360396,"accession_number":"0001867096-26-000048","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-06-30T20:06:32+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Xeris appoints Nerissa Kreher to board; CEO John Shannon named Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Nerissa Kreher appointed to board effective July 1, 2026, expanding board to eight members.","CEO John Shannon named Chair of the Board effective July 1, 2026.","Marla Persky transitions to Lead Independent Director.","Dr. Kreher is CMO of Alltrna and has over 20 years of rare disease experience.","Dr. Kreher received initial equity award of ~$450,000 in options and RSUs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":982077,"accession_number":"0001867096-26-000045","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-06-11T11:16:14+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Xeris Biopharma exchanges ~69% of 8% Convertible Notes due 2028 for cash and stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered private exchange to retire ~$23M (69%) of 8% Convertible Senior Notes due 2028.","Exchange consideration: $23M cash plus shares based on 21-day VWAP; ~4.6M shares if price is $6.71.","After exchange, $10.5M notes remain outstanding; annual interest savings ~$2M.","Expected close around July 15, 2026; Morgan Stanley acted as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":888517,"accession_number":"0001867096-26-000034","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-06-05T20:14:05+00:00","items":["5.07"],"status":"ready","headline":"Xeris shareholders elect Halkuff and Johnson as directors; approve auditor and say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dawn Halkuff elected with 62.6M for, 24.9M withhold; John Johnson with 52.7M for, 34.8M withhold.","Auditor Ernst & Young ratified for FY2026 with 125.8M for, 1.0M against, 1.4M abstain.","Advisory say-on-pay approved with 82.2M for, 4.7M against, 0.6M abstain; broker non-votes 40.8M.","Meeting quorum of 128.3M shares from 172.6M outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96404,"accession_number":"0001867096-26-000027","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma Q1 revenue up 43% to $82M; Recorlev nearly doubles to $50M; raises FY guidance to $380-390M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $82.5M, up 43% YoY; total revenue $83.1M, up 38%. Net income $2.2M vs net loss $9.2M.","Recorlev net revenue $49.8M, up 95% driven by patient demand; Gvoke flat at $20.8M; Keveyis $11.9M, up 4%.","Adjusted EBITDA $15.1M, improvement of $10.7M YoY; gross margin improved to 87% from 85%.","Raises FY2026 total revenue guidance; tightens range to $380-390M (>30% growth at midpoint).","Plans Phase 3 initiation of XP-8121 later in 2026; commercial team expansion completed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":83127000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96403,"accession_number":"0001867096-26-000020","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jeffrey Sherman to retire from Xeris Biopharma board at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jeffrey Sherman notified Board of his retirement and will not stand for reelection at the 2026 Annual Meeting.","Sherman will continue serving on Compensation and Nominating/Governance committees until his term expires.","Board reduced from eight to seven directors effective after Sherman's term ends at the 2026 Annual Meeting.","Sherman stated his retirement is not due to any disagreement with the company or its management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110284,"accession_number":"0001867096-26-000012","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma reports record Q4 revenue $85.8M (+43% YoY); net income $11.1M, provides FY2026 guidance $375-390M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $85.8M (+42.8% YoY); net income $11.1M vs net loss $5.1M in Q4 2024.","Recorlev Q4 revenue $45.3M (+100% YoY); FY2025 total revenue $291.8M (+43.7% YoY).","FY2026 total revenue guidance $375M-$390M, >30% growth at midpoint.","Adjusted EBITDA Q4 $25.1M, improvement of $16.8M vs prior year.","Company expects timely execution of XP-8121 Phase 3 trial; remains focused on capital deployment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110283,"accession_number":"0001867096-26-000010","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xeris Biopharma sues Torrent, Somerset over Recorlev patent infringement","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed Hatch-Waxman lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics over ANDA for generic Recorlev.","Lawsuit alleges infringement of four Orange Book patents expiring March 2040 (U.S. Patent Nos. 11,020,393, 11,278,547, 11,903,940, 12,377,096).","Seeks injunction to block generic competition until patent expiry in March 2040.","Recorlev also benefits from Orphan Drug Exclusivity through December 2028.","CEO John P. Shannon cites confidence in IP and intention to vigorously defend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110282,"accession_number":"0001867096-26-000004","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris expects record 2025 revenue of $292M, up 44% YoY; beats guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary full-year 2025 total revenue of $292M, exceeding $285-290M guidance range, reflecting 44% YoY growth.","Q4 Recorlev net revenue $45M; full-year Recorlev net revenue $139M.","Gvoke revenue grew >13% YoY; Keveyis patient base expanded vs. year-end 2024.","Positive Adjusted EBITDA delivered in each quarter of 2025.","Full 2025 results and 2026 outlook to be released March 2, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":291845000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126862,"accession_number":"0001867096-25-000161","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xeris Biopharma receives USPTO Notice of Allowance for XP-8121 patent application","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Patent allowance covers XP-8121 formulation for hypothyroidism, a novel product candidate.","Notice of Allowance indicates patentability; U.S. patent expected after administrative steps.","CEO John Shannon highlights milestone for meeting unmet medical need in hypothyroidism.","Xeris continues pursuing additional U.S. and international IP protection for LT4 technology.","XP-8121 leverages XeriSol platform for subcutaneous injection of difficult-to-formulate drugs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126861,"accession_number":"0001867096-25-000156","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Q3 product revenue $74M (+40% YoY); raises FY2025 guidance to $285-290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total product revenue $74.1M, up 40% YoY; total revenue $74.4M (+37% YoY).","Recorlev revenue $37.0M (+109% YoY); Gvoke $25.2M (+10%); Keveyis $11.9M (-2%).","Net income $0.6M vs net loss $15.7M in Q3 2024; adjusted EBITDA $17.4M.","FY2025 total revenue guidance raised to $285-290M from $280-290M, implying ~42% growth at midpoint.","CEO cites record quarter driven by increased patient demand across all three products."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":206038000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143659,"accession_number":"0001867096-25-000130","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma Q2 revenue up 49% to $71.5M; Recorlev +136%; raises FY guidance to $280-290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $71.5M (+49% YoY); net loss narrowed to $1.9M ($0.01/sh) from $15M ($0.10/sh).","Recorlev net revenue $31.4M (+136%) driven by 122% increase in average patients on therapy.","Gvoke revenue $23.5M (+17%); Keveyis $11.5M (-13%) on reduced shipments.","Adjusted EBITDA improved to $12.5M vs -$0.4M in Q2 2024.","Raised FY 2025 revenue guidance to $280-290M from $260-275M; long-term target $750M by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":131658000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161873,"accession_number":"0001867096-25-000104","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xeris Biopharma reports Annual Meeting voting results; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class I directors elected: Bormann (57.1M for), Brady (76.5M for), Kong (75.9M for).","Ratification of Ernst & Young as auditor for FY2025: 110.1M for, 0.7M against.","Advisory say-on-pay compensation vote passed: 72.2M for, 5.6M against, 0.9M abstain.","All proposals passed with required votes; no material changes to board or auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161872,"accession_number":"0001867096-25-000100","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xeris unveils long-range strategy; targets ~$750M revenue by 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirms 2025 total revenue guidance of $260-$275M and commitment to adjusted EBITDA positivity.","Expects total revenue of ~$750M by 2030, led by Recorlev growth.","Anticipates Recorlev annual net revenue of ~$1B in 2035; XP-8121 peak net revenue $1-3B.","Cites Recorlev revenue acceleration as inflection point to self-fund near- and long-term growth.","Hosts first Analyst and Investor Day on June 3, 2025, in New York City."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161871,"accession_number":"0001867096-25-000085","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Q1 revenue up 48% to $60.1M; Recorlev surges 141%; tightens FY guidance to $260-275M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $60.1M (+48% YoY); net loss $9.2M ($0.06 loss per share) vs prior year loss.","Recorlev revenue $25.5M (+141%); Gvoke $20.8M (+26%); Keveyis $11.4M (-13%).","Adjusted EBITDA positive $4.4M, an improvement of $8.4M vs Q1 2024.","FY 2025 total revenue guidance tightened to $260M-$275M from $255M-$275M.","Announces Analyst & Investor Day on June 3, 2025 in NYC to discuss Recorlev and XP-8121."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":60119000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179932,"accession_number":"0001867096-25-000054","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Xeris appoints James Brady to board, directors Ricki Fairley and John Schmid depart","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ricki Fairley resigned effective March 28, 2025; no disagreement with company.","John Schmid will not stand for reelection at 2025 Annual Meeting; board to reduce to eight members.","James Brady appointed as Class I director, will chair Audit Committee if reelected.","Brady brings 30+ years at AstraZeneca, most recently CFO of MedImmune; also serves on Verona Pharma (VRNA) board.","Brady received initial equity grant of 100,000 RSUs under non-employee director compensation plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179931,"accession_number":"0001867096-25-000034","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma reports record Q4 revenue $60M (+35% YoY); guides 2025 rev $255M-$275M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q4 total revenue $60.1M (+35% YoY); full-year $203.1M (+24% YoY)","Recorlev Q4 revenue $22.6M (+131% YoY); full-year $64.3M (+118% YoY)","Q4 net loss $5.1M (($0.03)/share); Adjusted EBITDA $8.3M; cash $71.6M","FY2025 revenue guidance $255M-$275M; expects positive Adjusted EBITDA going forward"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179930,"accession_number":"0001867096-25-000031","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Xeris appoints Dr. Anh Nguyen as CMO; Ken Johnson retiring April 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Anh Nguyen named Chief Medical Officer effective Feb 24, 2025.","Ken Johnson, SVP Global Dev & Medical Affairs, to retire April 1, 2025.","Nguyen will lead Medical, Regulatory, Preclinical/Clinical Dev, Pharmacovigilance.","Nguyen previously served as program medical lead for Gvoke NDA/MAA at Xeris."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179929,"accession_number":"0001867096-25-000017","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris exceeds FY2024 revenue guidance with $203M; Q4 positive cash flow; Recorlev up 28% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total FY2024 revenue expected at $203M, exceeding prior guidance of $198-202M (24% YoY growth).","Q4 2024 revenue projected at $60M (35% YoY growth); company generated positive cash flow in Q4.","Recorlev net revenue in Q4 anticipated to increase ~$5M or 28% sequentially, with record new starts.","Year-end cash, equivalents, and short-term investments expected to be over $71M.","Amgen terminated XeriJect license per portfolio assessment; no material impact on Xeris outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":203070000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196730,"accession_number":"0001867096-24-000183","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Q3 total revenue $54.3M record; guides FY to $198-$202M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $52.9M (+27% YoY); Gvoke $22.9M (+29%), Recorlev $17.7M (+119%), Keveyis $12.2M (-23%).","Net loss $15.7M ($0.11 EPS); excludes CEO succession restructuring costs of $6.1M gives adjusted EPS ($0.06).","FY 2024 total net revenue guidance raised to $198-202M from prior $190-200M; year-end cash guided to $68-72M.","Cash, cash equivalents and short-term investments $69.4M at Sept 30, 2024.","12th consecutive quarter of product revenue growth >20%; Recorlev patient count +125% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":142971000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213027,"accession_number":"0001867096-24-000157","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma Q2 revenue $48.1M (+26% YoY); raises FY revenue guidance to $190-200M; appoints John Shannon CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue of $48.1M (+26% YoY); product revenue record $46.5M.","Recorlev revenue surged 86% YoY to $13.3M; Gvoke up 28% to $20.0M; Keveyis down 7% to $13.1M due to generics.","Tightens FY2024 revenue guidance to $190-200M (from $175-200M) and year-end cash to $60-75M.","John Shannon appointed CEO and Kevin McCulloch promoted to President & COO as part of succession plan.","Net loss of $15.0M ($0.10 per share); cash and equivalents $77.6M at June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":88703000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213026,"accession_number":"0001867096-24-000137","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xeris Biopharma promotes Kevin McCulloch to President and COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin McCulloch, former Chief Commercial Officer, was promoted to President and COO effective August 1, 2024.","McCulloch will receive an annual base salary of $520,000 and a target annual incentive of 50% of base salary.","He was granted 150,000 restricted stock units vesting over 3 years and 200,000 stock appreciation rights vesting at 2 years.","Severance includes 1.25x salary plus target incentive if terminated without cause, or 1.5x if within 12 months after a change in control.","McCulloch reports to CEO John Shannon and joined Xeris in 2018 as SVP of Global Operations and Business Development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213025,"accession_number":"0001867096-24-000124","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Xeris CEO Paul Edick steps down; John Shannon named CEO; Q2 revenue >$47M (+23% YoY)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Paul R. Edick transitions to Senior Advisor effective Aug 1, 2024; John Shannon (President & COO) appointed new CEO and Board member.","Marla S. Persky appointed Chairperson of the Board effective Aug 1, 2024.","Preliminary Q2 2024 total revenue exceeds $47.0M, representing >23% growth over prior year.","Year-end 2024 cash guidance reaffirmed at $55M to $75M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232145,"accession_number":"0001867096-24-000102","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Xeris stockholders approve all proposals; ESPP shares increased by 6.64M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Third director nominees elected: Edick, Fairley, Persky (58.5M, 58.5M, 47.4M for).","Ernst & Young ratified as auditor for FY2024 (99.5M for).","Advisory vote on executive compensation approved (57.8M for); frequency set at 1 year.","ESPP amendment approved: evergreen provision removed; shares increased by 6,636,632 to 8,854,709.","Broker non-votes on director election and advisory items: ~36.2M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232144,"accession_number":"0001867096-24-000062","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma Q1 total revenue $40.6M (+22% YoY); tightens FY 2024 guidance to $175M-$200M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $40.3M (+24.8% YoY); Recorlev revenue $10.6M (+136.7%).","Net loss $19.0M ($0.14/share); cash $87.4M at March 31, 2024 (up from $72.5M).","Entered exclusive license with Amgen for XeriJect teprotumumab; up to $75M milestones plus royalties.","Entered collaboration with Beta Bionics for XeriSol glucagon in bi-hormonal pumps.","Tightened FY 2024 total revenue guidance to $175M-$200M; lowered Hayfin debt rate by 2.05%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":40638000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250411,"accession_number":"0001867096-24-000024","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["1.01","2.02","2.03","8.01","9.01"],"status":"ready","headline":"Xeris reports Q4 total revenue $44.4M (+34% YoY); refinances debt with $200M Hayfin facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $44.4M, +34% YoY; full-year 2023 revenue $163.9M, +49% YoY.","Net loss in Q4 $13.4M ($0.10 loss per share); year-end cash $72.5M.","FY2024 guidance: total net revenue $170M-$200M; year-end cash $55M-$75M.","Refinanced existing $150M Hayfin loan with new $200M term loan; additional $15.2M available to redeem 2025 notes.","New loan bears 6.95% + SOFR (floor 2%) interest; maturity March 2029; reduces borrowing cost by 2.05%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250410,"accession_number":"0001867096-24-000003","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris expects Q4 cashflow positive, 2023 revenue at high end of $160M-$165M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue for FY 2023 expected at high end of prior $160M-$165M guidance.","Ending cash, equivalents & short-term investments >$72M, above $65M-$70M guidance.","Q4 2023 expected to be cashflow positive; Q4 & FY results on or about March 6, 2024.","2024 outlook: revenue growth, flat opex, declining burn, sufficient cash for obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":163914000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267950,"accession_number":"0001867096-23-000136","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Record Q3 revenue $48.3M (+63% YoY); tightens FY23 guidance to $160-165M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $48.3M, up 63% YoY and 27% QoQ; product revenue $41.7M, up 41% YoY.","Gvoke net revenue $17.7M (+30% YoY); 58k prescriptions, 31% retail TRx glucagon share.","Recorlev net revenue $8.1M (+$5.6M vs prior year); patients on therapy up 203%.","Cash, cash equivalents and short-term investments $66.0M; expects cash flow breakeven in Q4 2023.","Tightened full-year 2023 revenue guidance from $155-165M to $160-165M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":119524000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267949,"accession_number":"0001867096-23-000130","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xeris raises year-end cash guidance to $65-70M, tightens 2023 revenue to $155-165M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Year-end cash, equivalents, and short-term investments guided to $65-70M (up from $55-65M).","Full-year 2023 total revenue guidance tightened to $155-165M from $145-165M.","Received $6M milestone payment from Amgen for subcutaneous TEPEZZA formulation success.","Company reaffirms cash flow breakeven in Q4 2023; net cash outflow H2 expected ~$11-16M.","Q3 2023 earnings call scheduled for November 9, 2023 at 8:30 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285185,"accession_number":"0001867096-23-000125","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Xeris Biopharma exchanges $32M of 5% convertible notes for $33.6M of new 8% notes due 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $31,975,000 of 5% Convertible Senior Notes due 2025 for $33,574,000 of new 8.00% Convertible Senior Notes due 2028.","New notes bear 8.00% interest, payable semi-annually; maturity July 15, 2028.","Initial conversion rate is 326.7974 shares per $1,000 principal, implying ~$3.06 per share.","Notes are senior unsecured, guaranteed by Xeris Pharmaceuticals, issued to QIBs via Section 4(a)(2) exemption.","Company may redeem notes after July 20, 2026 if stock price exceeds 130% of conversion price for 20 of 30 trading days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285184,"accession_number":"0001867096-23-000121","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2023-09-27T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Xeris exchanges $32M of 5% 2025 notes for $33.6M of 8% 2028 notes; extends debt maturity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $31,975,000 of 5% convertible notes due 2025 for $33,574,000 of 8% notes due July 2028.","Conversion price unchanged at ~$3.06 per share (~68% premium to Sept 26 closing price).","Only ~$15.2M of original 2025 notes remain; no other debt due until 2027.","Notes are senior unsecured; interest payable semi-annually starting Jan 15, 2024.","Redeemable after July 20, 2026 if stock exceeds 130% of conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285183,"accession_number":"0001867096-23-000110","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Q2 revenue $38.0M record, up 50% YoY; tightens FY23 guidance upward","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record total revenue $38.0M, QoQ +14%, YoY +50%; product revenue $36.9M (+46%).","Gvoke net revenue $15.6M (+36%), Keveyis $14.1M (+10%), Recorlev $7.2M.","FY23 revenue guidance tightened to $145M-165M from $135M-165M; cash utilization reduced to $57M-67M.","Cash, equivalents and short-term investments $80.7M at June 30; on track for cash flow breakeven by year-end.","Net loss $19.8M ($0.14 per share); Phase 2 study of XP-8121 (levothyroxine) began dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":71204000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305042,"accession_number":"0001867096-23-000106","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Founder and CSO Steven Prestrelski resigns, becomes Senior Scientific Advisor at Xeris Biopharma","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Prestrelski, PhD, Founder and Chief Scientific Officer, resigned effective June 30, 2023.","He entered a consulting agreement as Senior Scientific Advisor from July 1, 2023 to January 31, 2025.","The consulting agreement covers predefined services; no further financial terms disclosed.","Transition follows founder's departure from executive role but retention as advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305041,"accession_number":"0001867096-23-000089","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xeris Biopharma stockholders elect three Class II directors and ratify E&Y as auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dawn Halkuff elected with 53.2M for, 4.4M withhold, 31.2M broker non-votes.","John Johnson elected with 42.9M for, 14.7M withhold, 31.2M broker non-votes.","Jeffrey Sherman elected with 51.3M for, 6.3M withhold, 31.2M broker non-votes.","Ratification of Ernst & Young as auditor approved: 87.8M for, 0.8M against, 0.2M abstain.","No other matters were submitted to a vote at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305040,"accession_number":"0001867096-23-000066","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Q1 revenue $33.2M (+50% YoY); reaffirms 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $33.2M vs $22.1M in Q1 2022; Gvoke net revenue $15.0M (+21%), Keveyis $12.8M (+37%), Recorlev $4.5M.","Net loss $16.8M ($0.12 per share); cash & investments $95.1M at March 31, 2023.","2023 guidance: revenue $135M-$165M; cash from ops ($57M)-($77M); year-end cash $45M-$65M.","Announced XeriJect collaboration with Regeneron for two undisclosed monoclonal antibodies.","Appointed Ricki Fairley to Board of Directors, increasing board to nine members."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":33196000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324516,"accession_number":"0001867096-23-000045","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xeris expands board to 9, appoints Ricki Fairley as Class III director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ricki Fairley appointed to board on March 27, 2023, expanding board from 8 to 9 members.","Fairley brings 35+ years of marketing experience; currently CEO of TOUCH, The Black Breast Cancer Alliance.","Received 85,000 RSUs vesting in equal annual installments over three years.","Fairley's compensation follows the Non-Employee Director Compensation Policy filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324515,"accession_number":"0001867096-23-000037","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Xeris Biopharma replaces KPMG with Ernst & Young as independent auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed KPMG as independent registered public accounting firm on March 13, 2023.","KPMG's reports for FY2022 and FY2021 had no adverse opinion except for a lease accounting change.","No disagreements or reportable events occurred during the audit periods or interim period through March 13, 2023.","Ernst & Young engaged as new independent auditor for the fiscal year ending December 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324514,"accession_number":"0001867096-23-000027","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris reports Q4 product revenue $32.5M (+52% YoY); guides 2023 revenue $135-165M, cash flow breakeven Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product revenue $32.5M, up 52% YoY; full-year 2022 net product revenue $109.3M, up 38% pro forma.","Q4 net loss $12.9M ($0.10/sh); full-year net loss $94.7M ($0.70/sh). Cash at Dec 31, 2022: $122.0M.","2023 guidance: total revenue $135M-$165M, cash utilization $57-77M, year-end cash $45-65M; targets cash flow breakeven in Q4 2023.","Announced research collaboration with Horizon Therapeutics for XeriJect formulation of TEPEZZA; $2.75M upfront payment.","Gvoke NRx market share >28% at Feb 2023; Recorlev granted FDA orphan-drug exclusivity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324513,"accession_number":"0001867096-23-000006","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2023-01-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Xeris Biopharma amends credit deal to allow Letter of Financial Support to Australian unit","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Amendment No. 2 signed Jan 19, 2023; permits Xeris Pharma to issue a Letter of Financial Support to its Australian subsidiary.","Amendment modifies Credit Agreement dated March 8, 2022, with Hayfin Services as administrative agent.","No changes to principal, interest rate, or maturity under the existing credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324512,"accession_number":"0001867096-23-000003","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris expects 2022 net product revenue at top of $105M-$110M guidance, cash >$120M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Expects 2022 net product revenue at top of guidance range of $105M-$110M.","Year-end cash, cash equivalents, and short-term investments >$120M, above previous $110M-$120M range.","FDA approved a generic version of Keveyis (dichlorphenamide); company believes it can defend the franchise.","Does not anticipate need to raise equity to fund operations, citing commercial momentum and cash position.","Q4 and FY22 financial results to be reported on or about March 8, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":110248000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342381,"accession_number":"0001867096-22-000123","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma Q3 product revenue $29.6M, record; raises cash guidance to $110-120M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $29.6M, up 31% pro forma YoY; Gvoke $13.7M (+24%), Keveyis $13.4M, Recorlev $2.5M.","Full-year net product revenue guidance tightened to $105-110M; year-end cash guidance raised to $110-120M.","Net loss $21.8M ($0.16/share) for Q3; cash & investments $93.4M at Sept 30.","Positive Phase 1 topline for subcutaneous levothyroxine (XP-8121); FDA Type C meeting requested.","On track for $50M in synergies by year-end 2022 and cash flow breakeven by year-end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":77104000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342380,"accession_number":"0001867096-22-000117","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2022-10-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xeris reports positive Phase 1 data for SC levothyroxine (XP-8121); weekly dosing matches daily oral","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 study (n=60) shows proof-of-concept for once-weekly SC XP-8121 with steady-state exposure similar to daily oral Synthroid.","Population PK model implies dose conversion factor of 4X: weekly 1200 μg SC equivalent to daily 300 μg PO levothyroxine.","XP-8121 well tolerated at all doses (600, 1200, 1500 μg); safety profile comparable to Synthroid 600 μg PO.","Company expects FDA End-of-Phase 1 meeting feedback by end of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342379,"accession_number":"0001867096-22-000111","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2022-10-03T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Xeris Biopharma enters amended lease for 87,032 sq ft Chicago HQ; base rent $52.50/sq ft","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Xeris Pharma leases 87,032 sq ft office/lab at 1375 W. Fulton, Chicago; term through 2037.","Annual base rent $52.50/sq ft in year one, escalating 2.5% annually; rent abatement for first 12 months.","Letter of credit increased from $408,263 to $3,247,808 to secure lease obligations.","Company to relocate HQ to premises in H1 2023; current HQ at 180 N. LaSalle to be subleased.","Credit agreement amended to permit issuance of the letter of credit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359103,"accession_number":"0001867096-22-000102","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Biopharma Q2 net product revenue record $25.3M, reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 net product revenue $25.3M, up 15% from Q1 and 34% pro forma YoY.","Gvoke net revenue $11.5M (+30% YoY); Keveyis $12.8M (+28% pro forma); Recorlev $1.0M.","Cash $111.6M at quarter-end; reaffirms FY net product revenue $105M-$120M, cash flow breakeven by end 2023.","Net loss $26.2M ($0.19/sh) in Q2, $59.9M ($0.44/sh) in H1.","Ogluo commercial partner Tetris Pharma acquired by Arecor Therapeutics in August 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":47379000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377919,"accession_number":"0001867096-22-000070","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2022-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xeris Biopharma stockholders elect three Class I directors and ratify KPMG as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1: All three Class I director nominees elected: Bormann (41.5M for), Kong (46.4M for), Schmid (41.5M for).","Proposal 2: Ratification of KPMG LLP as auditor for FY 2022 passed with 79.0M for, 687K against, 110K abstain.","Broker non-votes totaled 32.1M shares on director elections.","Annual meeting held June 8, 2022; 135.5M shares outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377918,"accession_number":"0001867096-22-000056","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris Q1 net product revenue $21.9M (+33% pro forma); net loss $33.7M; reaffirms FY22 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net product revenue $21.9M, up 33% pro forma vs prior year; net loss $33.7M ($0.25/share).","Cash and investments $132.1M at quarter end; completed $100M draw on new $150M Hayfin term loan.","Affirms 2022 guidance: revenue $105M-$120M, year-end cash $90M-$110M, cash flow breakeven by end-2023.","Gvoke prescriptions topped 30,000 in Q1, retail TRx market share ~22%; launched Recorlev and Gvoke Kit.","Entered $30M securities purchase agreement with Armistice Capital; issued ~10.2M shares and warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":22073000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396243,"accession_number":"0001867096-22-000033","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["1.01","2.02","2.03","8.01","9.01"],"status":"ready","headline":"Xeris closes $150M Hayfin debt facility, reports FY2021 product revenue $79M (+56%) and guides FY2022 $105M-$120M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Xeris drew $100M from new $150M Hayfin term loan (9%+SOFR, warrants at $2.28, 5-yr maturity); repaid $43.5M Oxford/SVB debt.","FY2021 net product revenue $79M (pro forma), up 56% YoY; net loss $122.7M ($1.55/share) vs $91.1M ($2.14/share) in 2020.","FY2022 revenue guidance $105M-$120M; year-end cash $90M-$110M; cash flow breakeven targeted by end of 2023.","Gvoke prescriptions up 85% in Q4, retail share ~17%; Keveyis at high end of $38-40M guidance; Recorlev launched Feb 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396242,"accession_number":"0001867096-22-000023","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2022-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xeris files Strongbridge unaudited 9M 2021 financials: net loss $31.6M, rev $29.9M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Strongbridge nine months ended Sep 30, 2021: net loss $31.6M vs $33.1M prior-year.","Revenue $29.9M vs $22.5M prior-year, primarily from Keveyis sales.","Cash and equivalents $55.3M; accumulated deficit $337.2M as of Sep 30, 2021.","Acquisition by Xeris closed Oct 5, 2021; filing satisfies SEC requirement for acquired company financial statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396241,"accession_number":"0001867096-22-000017","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2022-01-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xeris reaffirms 2021 net sales guidance at high-end $76-80M, 55% YoY growth","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary 2021 pro forma net sales expected at high-end of $76-80M guidance, ~55% growth vs 2020.","Year-end 2021 preliminary cash, equivalents, and investments ~$102M.","Over 20M Medicaid lives in IL, TN, PA, OH, CA now have unrestricted access to Gvoke as of Jan 1, 2022.","Third product Recorlev approved; launch in near term; additional $30M raised early 2022.","Full Q4 and FY 2021 results and 2022 guidance expected in March 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396240,"accession_number":"0001193125-22-000317","cik":1867096,"company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","form_type":"8-K","filed_at":"2022-01-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Xeris Biopharma raises $30M in private placement with Armistice Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $30M from sale of 10.2M shares at $2.93/share (closing price Dec 31, 2021).","Warrants to purchase up to 5.1M shares at $3.223/share, exercisable immediately for 5 years.","Net proceeds to support operations, commercial products, clinical trials, working capital.","Private placement expected to close Jan 3, 2022; resale registration statement to be filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1022040000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-01-03T23:59:59+00:00|396240"}